HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Cosmetics In Brief: P&G’s DUO Buffers; Clinique Anti-Aging Booster; Lime Crime Pop On Nails; More

This article was originally published in The Rose Sheet

Executive Summary

P&G and Unilever/Dove launch new shower items for body cleansing and dandruff treatment, respectively; Meanwhile, new Clinique Fresh Pressed Daily Booster rejuvenates skin when added to users’ routine moisturizers. More on recent cosmetic launches.

You may also be interested in...



L'Oreal, Lauder Optimistic About Innovations In Challenging 2017 Climate

The pure-play beauty leaders continue to grow in a challenging global climate, both looking to recent and upcoming launches to keep them on an upward trajectory.

FDA Slaps Color Cuffs On Lime Crime For Unsafe Additive Use

Quirky L.A. makeup brand uses ferric ferrocyanide and ultramarines – color additives permitted only in externally applied cosmetics – in one of its Velvetines liquid-to-matte lipsticks, according to the agency's July 29 warning letter. The unapproved color-additive use renders the Lime Crime product adulterated, FDA says.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel